AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Bionano Increases OGM Installation Target to 25 for 2025 Amid Rising Consumables and Software Revenue
ByAinvest
Friday, Aug 15, 2025 4:44 am ET1min read
Bionano Genomics raised its 2025 OGM installation target to 25, driven by a 16% increase in consumables and software revenue. The company's CEO described Q2 2025 as "solid," citing the positive effects of the strategic shift made in September 2024, which prioritized supporting routine users of Bionano's optical genome mapping (OGM) technology.
Bionano Genomics Inc. (NASDAQ: BNGO) has raised its 2025 optical genome mapping (OGM) installation target to 20-25, reflecting a strategic shift towards supporting routine users of its technology. The company reported a 16% increase in consumables and software revenue in Q2 2025, a significant driver behind this upward revision. CEO R. Erik Holmlin described the quarter as "solid," attributing the positive performance to the strategic changes implemented in September 2024.The company's Q2 2025 results highlighted several key developments. Total revenue stood at $6.73 million, a 13% decrease year-over-year (YOY), but it exceeded analyst estimates by 2.6% [1]. Gross margin expanded to 52%, up from 35% in Q2 2024, indicating improved profitability. Operating expenses fell sharply by 42% to $11.3 million, contributing to a narrower net loss. The installed system base increased to 378, reflecting stable demand within key customer segments.
Flow cell sales climbed 17% in Q2 2025, with 7,233 units sold compared to 6,165 in Q2 2024. The company's platform-agnostic VIA software continued to see solid adoption among high-usage accounts, with a 17% YOY increase in flow cell sales. Regulatory momentum also continued, with the American Medical Association establishing a second Category I Current Procedural Terminology (CPT) code for OGM in genome-wide cytogenomic analysis, a significant precursor for gaining insurance reimbursement.
Bionano's focus on routine users and the integration of powerful software tools like VIA and Solve have driven a shift in commercial strategy, contributing to a 16% YOY increase in consumables and software revenue. The company remains committed to its digital pathology strategy, which offers significant upside potential.
References:
[1] https://seekingalpha.com/news/4485650-bionano-genomics-reports-q2-results
[2] https://finance.yahoo.com/news/bionano-genomics-inc-bngo-q2-072343258.html
[3] https://www.nasdaq.com/articles/bionano-genomics-posts-q2-margin-gain
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet